欢迎来到 CSNpharm! 产品仅用于科研!
首页 Compound Arrays 促销产品
400-920-2911 sales@csnpharm.cn    

CDK

CDK

货号 产品名 CAS号 信息
CSN25265 Trilaciclib 1374743-00-6 Trilaciclib is an inhibitor of CDK4 and CDK6 with IC50s of 1 nM and 4 nM, respectively.
CSN24801 TP353   1253799-29-9 TP353 is a CDK7 inhibitor.
CSN20233 TG693 885272-55-9 TG693, an orally available inhibitor of CLK1, promotes the skipping of the endogenous mutated exon 31 in Duchenne muscular dystrophy (DMD) patient-derived cells and increased the production of the functional exon 31-skipped dystrophin protein.
CSN22563 TG003 300801-52-9 TG003 is a potent, reversible ATP-competitive inhibitor of Cdc-2 like kinase (Clk) with IC50s of 20 nM and 15 nM for Clk1/Sty and Clk4.
CSN26130 TAK-931 1330782-76-7 TAK-931 is an oral CDC7-selective inhibitor as a candidate clinical anticancer drug. It induced S phase delay and replication stress.
CSN26176 SY-1365 1816989-16-8 SY-1365 is a first-in-class selective CDK7 inhibitor with Ki of 17.4 nM.
CSN25349 SR-4853 2387704-62-1 SR-4835 is a potent, highly selective and ATP competitive dual inhibitor of CDK12/CDK13 with IC50 of 99 nM, Kd of 98 nM for CDK12 and Kd of 4.9 nM for CDK13. It acts in synergy with DNA-damaging chemotherapy and PARP inhibitors and provokes triple-negative breast cancer (TNBC) cell death.
CSN19761 Roniciclib 1223498-69-8 Roniciclib is an orally bioavailable cyclin dependent kinase (CDK) inhibitor with potential antineoplastic activity, selectively binds to and inhibits the activity of CDK1/Cyclin B, CDK2/Cyclin E, CDK4/Cyclin D1, and CDK9/Cyclin T1, serine/threonine kinases that play key roles in the regulation of the cell cycle progression and cellular proliferation.
CSN22310 CDK9-PROTAC 2118356-96-8 PROTAC CDK9 Degrader-1 is a CRBN-recruiting PROTAC selectively targeting on CDK9, consist of a CDK9 ligand (aminopyrazole analog) linked to a CRBN E3 ligand thalidomide.
CSN25543 PNU 112455A 21886-12-4 PNU112455A HCl is an ATP site competetive inhibitor of CDK2 and CDK5. The Km for binding to the ATP site of CDK2 and CDK5 is 3.6 and 3.3 mM, respectively.
CSN25344 NU6140 444723-13-1 NU6140 is a selective CDK2 inhibitor with IC50 value of 0.94μM, as well as potently inhibits Aurora kinase A/B with IC50 values of 0.035 and 0.067μM, respectively.
CSN25261 NSC-95397 93718-83-3 NSC 95397 is irreversible Cdc25 dual specificity phosphatase inhibitor with Ki values of 32, 96, and 40 nM for Cdc25A, Cdc25B, and Cdc25C, respectively.
CSN26115 JSH-150 2247481-21-4 JSH-150 is a highly selective CDK9 kinase inhibitor with IC50 value of 1nM. It dose-dependently inhibited the phosphorylation of RNA Pol II, suppress the expression of MCL-1 and c-Myc, arrested the cell cycle and induced the apoptosis in the leukemia cells.
CSN22284 JH-XI-10-02 2209085-22-1 JH-XI-10-02 is a PROTAC selectively targeting on CDK8 with IC50 value of 159nM, and is consist of a warhead target on CDK8 (a Cortistatin A derivate) linked to CRBN ligand Pomalidomide.
CSN19698 Lerociclib 1628256-23-4 G1T38 is a potent, selective, and orally bioavailable CDK4/6 inhibitor with unique pharmacokinetic and pharmacodynamic properties, which result in high efficacy against CDK4/6 dependent tumors while minimizing the undesirable on-target bone marrow activity.
CSN21361 FN-1501 1429515-59-2 FN-1501 is a potent inhibitor of FLT3 and CDK, with IC50s of 2.47, 0.85, 1.96, and 0.28 nM for CDK2/cyclin A, CDK4/cyclin D1, CDK6/cyclin D1 and FLT3, respectively; has anticancer activity.
CSN24779 EHT 5372 1425945-60-3 EHT 5372 is a strong inhibitor of DYRK’s family kinases, with IC50s of 0.22, 0.28 nM for DYRK1A and DYRK1B, respectively.
CSN21181 CT7001 HCl 1805789-54-1 CT7001 HCl is a selective CDK7 inhibitor, with IC50s of 41 nM and 578 nM for CDK7/CycH/MAT1 and CDK2/cycE1, respectively.
CSN22379 CMPD 7 2220184-50-7 CMPD 7 is a potent and selective CDK12 inhibitor with an IC50 of 491 nM in enzymatic assay.
CSN20276 Clk Inhibitor T3 2109805-56-1 Clk inhibitor T3 is a highly selective, stable CLK inhibitor with high specificity to CLK1-3 protein isoforms.
CSN20232 Clk Inhibitor C21b 2101206-26-0 Clk inhibitor C21b, a potent inhibitor of Clk1 and -4 (IC50 = 7 and 2.3 nM, respectively), exhibits an unprecedented selectivity over Dyrk1A. It triggered the depletion of EGFR, HDAC1, and p70S6 kinase from the cancer cells, with potencies in line with the measured GI50 values.
CSN22366 CDK8/19-IN-1 1818427-07-4 CDK8/19-IN-1 is a potent, selective and oral bioavailable CDK8/19 dual inhibitor, with IC50s of 0.46 nM, 0.99 nM and 270 nM for CDK8, CDK19 and CDK9, respectively.
CSN22368 CDK8-IN-4 1613638-82-6 CDK8-IN-4 is an inhibitor of CDK8 extracted from patent WO2014090692A1, compound example 16, with an IC50 of 0.2 nM.
CSN22367 CDK8-IN-3 1884500-15-5 CDK8-IN-3 is an inhibitor of CDK8 extracted from patent WO2016041618A1, compound example 1.7.
CSN26129 CDK2 inhibitor 73 2079895-42-2 CDK2 inhibitor 73 is a selective CDK2 inhibitor with IC50 value of 44nM.
CSN19756 CDC7 Inhibitor C10C 1330781-04-8 CDC7 inhibitor C10C is a high selective CDC7 inhibitor.
CSN23778 cc671 1618658-88-0 CC-671 is a selective inhibitor of TTK (Mps1) and CLK2 with IC50s of 5 nM and 3 nM, respectively.
CSN23969 BSJ-03-123 2361493-16-3 BSJ-03-123 is a PROTAC selectively targeting on CDK6, consist of a warhead palbociclib (a CDK inhibitor) linked to a CRBN ligand pomalidomide.
CSN25245 BS-194 1092443-55-4 BS-194 is a selective and potent CDK inhibitor with IC50 values of 3, 30, 30, 250, and 90nM for CDK2, CDK1, CDK5, CDK7, and CDK9, respectively.
CSN17259 Briciclib 865783-99-9 Briciclib is a small molecule that suppresses cyclin D1 accumulation in cancer cells.
CSN20540 BRD6989 642008-81-9 BRD6989 selectively upregulates IL-10 through inhibiting CDK8 activity.
CSN24819 Bohemine 189232-42-6 Bohemine is a potent and selective, cell-permeable, cyclin-dependent kinase (CDK) inhibitor with IC50 = 1 µM. Bohemine is structurally similar to Olomoucine and Roscovitine.
CSN25300 BI-1347 2163056-91-3 BI-1347 is a potent CDK8 inhibitor with an IC50 of 1.1 nM.
CSN21503 AZD5438 602306-29-6 AZD5438 is a potent inhibitor of CDK1/2/9 with IC50 of 16/6/20 nM.
CSN24735 AZD4573 2057509-72-3 AZD4573 is a potent and selective CDK9 inhibitor with with nanomolar.
CSN25869 Atuveciclib 1414943-94-4 Atuveciclib is an orally available and selective PTEFb/CDK9 inhibitor for the treatment of cancer.
CSN21360 AMG925 HCl 1401034-19-2 AMG 925 HCl is a potent, selective, and orally available FLT3/CDK4 dual inhibitor with IC50s of 2±1 nM and 3±1 nM, respectively.
CSN22673 Alsterpaullone 237430-03-4 Alsterpaullone is a potent CDK1 and 2 inhibitor with IC50s of 0.035 and 0.08 μM, respectively. It also inhibits GSK-3β and Lck with IC50s of 0.11 and 0.47 μM, respectively.
CSN22626 (R)-CR8 294646-77-8 (R)-CR8 is a cyclin dependent kinase (cdk) inhibitor with IC50 of 0.036 - 0.07 and 0.09 - 0.8 μM for cdk2 and cdk1,respectively.
CSN26940 (-)-((2-((5-Fluoro-4-(4-fluoro-2-methoxyphenyl)pyridin-2-yl)amino)pyridin-4-yl)methyl)(imino)(methyl)-l6-sulfanone 1610358-59-2 (-)-BAY-1251152 is an enanthiomer of BAY-1251152 with rotation (-). BAY-1251152 is a potent and highly selective PTEF/CDK9 inhibitor.
CSN21345 (+)-BAY-1251152 1610358-56-9 (+)-BAY-1251152 is a CDK9 inhibitor, Phase 1 of Neoplasms.
<< PREV 1 2 3 4 NEXT >>